Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia

We describe the changing pattern of analgesic and new central acting drug (NCAD) use (pregabalin, duloxetine, milnacipran) in fibromyalgia and measure NCAD effectiveness in clinical practice.

[1]  K. Barker.  Listening to Lyrica: contested illnesses and pharmaceutical determinism. , 2011, Social science & medicine.

[2]  F. Wolfe,et al.  Do We Need Core Sets of Fibromyalgia Domains? The Assessment of Fibromyalgia (and Other Rheumatic Disorders) in Clinical Practice , 2011, The Journal of Rheumatology.

[3]  C. Sommer,et al.  Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. , 2011, Rheumatology.

[4]  F. Wolfe,et al.  The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. , 2011, Rheumatology.

[5]  F. Wolfe,et al.  The Hawthorne Effect, Sponsored Trials, and the Overestimation of Treatment Effectiveness , 2010, The Journal of Rheumatology.

[6]  C. Sommer,et al.  Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. , 2010, The journal of pain : official journal of the American Pain Society.

[7]  M. Detke,et al.  Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. , 2010, Seminars in arthritis and rheumatism.

[8]  D. Turk,et al.  Guidelines on the management of fibromyalgia syndrome – A systematic review , 2010, European journal of pain.

[9]  M. Briley.  Drugs to treat fibromyalgia - the transatlantic difference. , 2010, Current opinion in investigational drugs.

[10]  H. Moldofsky,et al.  A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia , 2009, The Clinical journal of pain.

[11]  B. Herman,et al.  Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia , 2009 .

[12]  Patrick Dattalo,et al.  Statistical Power Analysis , 2008 .

[13]  G. Oster,et al.  Characteristics and healthcare costs of patients with fibromyalgia syndrome , 2007, International journal of clinical practice.

[14]  B. Collett,et al.  Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment , 2006, European journal of pain.

[15]  P. Wainwright,et al.  Open label extension studies: research or marketing? , 2005, BMJ : British Medical Journal.